[go: up one dir, main page]

UY26143A1 - Derivados heterocíclicos útiles como agentes anticancerosos - Google Patents

Derivados heterocíclicos útiles como agentes anticancerosos

Info

Publication number
UY26143A1
UY26143A1 UY26143A UY26143A UY26143A1 UY 26143 A1 UY26143 A1 UY 26143A1 UY 26143 A UY26143 A UY 26143A UY 26143 A UY26143 A UY 26143A UY 26143 A1 UY26143 A1 UY 26143A1
Authority
UY
Uruguay
Prior art keywords
cancer agents
heterocyclic derivatives
useful heterocyclic
compounds
above compounds
Prior art date
Application number
UY26143A
Other languages
English (en)
Inventor
Thomas George Gant Y Mark Noe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY26143A1 publication Critical patent/UY26143A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula 1 y a las sales, profármacos y solvatos farmacéuticamente aceptables de los mismos, en la que Z, X, X1, R1, R2 y R3 son tal como se define en la presente, así como también se refiere a composiciones farmacéuticas que contienen los compuestos anteriores para el tratamiento de trastornos mediados por angiogénesis en mamíferos por administración de los compuestos anteriores.
UY26143A 1999-05-19 2000-05-15 Derivados heterocíclicos útiles como agentes anticancerosos UY26143A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13493399P 1999-05-19 1999-05-19

Publications (1)

Publication Number Publication Date
UY26143A1 true UY26143A1 (es) 2000-12-29

Family

ID=22465672

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26143A UY26143A1 (es) 1999-05-19 2000-05-15 Derivados heterocíclicos útiles como agentes anticancerosos

Country Status (21)

Country Link
US (1) US6380214B1 (es)
EP (1) EP1187826B1 (es)
JP (2) JP3692041B2 (es)
AR (1) AR029634A1 (es)
AT (1) ATE349440T1 (es)
AU (1) AU4137400A (es)
BR (1) BR0010746A (es)
CA (1) CA2374247C (es)
CO (1) CO5170417A1 (es)
DE (1) DE60032601T2 (es)
DZ (1) DZ3042A1 (es)
ES (1) ES2276681T3 (es)
GT (1) GT200000069A (es)
HN (1) HN2000000051A (es)
MA (1) MA26733A1 (es)
MX (1) MXPA01011920A (es)
PA (1) PA8494101A1 (es)
PE (1) PE20010152A1 (es)
TN (1) TNSN00104A1 (es)
UY (1) UY26143A1 (es)
WO (1) WO2000071532A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2725000A (en) 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2003522174A (ja) 2000-02-07 2003-07-22 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存性キナーゼの３−アミノピラゾール阻害剤
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
SI1401825T1 (sl) * 2001-06-11 2010-01-29 Virochem Pharma Inc Tiofenski derivati kot protivirusna sredstva za flavirusno infekcijo
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US6989451B2 (en) * 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
CA2489355A1 (en) * 2002-06-13 2003-12-24 Qlt Inc. Methods of using isothiazole derivatives to treat cancer or inflammation
SG149701A1 (en) * 2002-07-09 2009-02-27 Fasgen Llc Methods of treating microbial infections in humans and animals
CA2491802C (en) * 2002-07-09 2012-04-10 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, and methods of use for same
MXPA05000950A (es) * 2002-07-25 2005-05-16 Pfizer Prod Inc Derivados de isotiazol utiles como agentes anticancerosos.
AU2003302665B2 (en) * 2002-11-15 2009-12-24 Symphony Evolution, Inc. Kinase modulators
PT1569929E (pt) * 2002-12-10 2010-06-18 Virochem Pharma Inc Compostos e métodos para o tratamento ou prevenção de infecções por flavivírus
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
TWI422583B (zh) * 2003-03-07 2014-01-11 參天製藥股份有限公司 具有以４-吡啶烷硫基為取代基之新穎化合物
JP2007511203A (ja) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
KR101139557B1 (ko) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
CN1918127B (zh) * 2004-02-17 2012-02-15 参天制药株式会社 具有引入了取代或无取代氨基的4-吡啶基烷硫基的环状化合物
WO2005085201A1 (ja) * 2004-02-17 2005-09-15 Santen Pharmaceutical Co., Ltd. 置換又は無置換アミノ基を導入した４－ピリジルアルキルチオ基を有する新規環式化合物
JP4626353B2 (ja) * 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物
AU2005223483B2 (en) 2004-03-18 2009-04-23 Zoetis Llc N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
JP5100390B2 (ja) * 2004-08-26 2012-12-19 ファイザー・インク イソチアゾール誘導体の製造方法
JP4585978B2 (ja) * 2005-03-03 2010-11-24 参天製薬株式会社 キノリルアルキルチオ基を有する新規環式化合物
AU2006246227B2 (en) * 2005-05-13 2011-04-28 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
KR20090086081A (ko) 2006-11-15 2009-08-10 바이로켐 파마 인코포레이티드 플라비바이러스 감염의 치료 또는 예방용 티오펜 유사체
CA2678735A1 (en) * 2007-02-26 2008-09-04 Santen Pharmaceutical Co., Ltd. Novel pyrrole derivative having ureido group and aminocarbonyl group as substituents
TW200911240A (en) * 2007-06-11 2009-03-16 Kyowa Hakko Kogyo Kk Anti-tumor agent
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
CN102625797B (zh) * 2009-06-25 2014-03-26 江苏迈度药物研发有限公司 作为激酶抑制剂的取代杂环化合物及其使用方法
AR092809A1 (es) 2012-03-16 2015-05-06 Axikin Pharmaceuticals Inc 3,5-diaminopirazol como inhibidor de quinasa
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
AR103264A1 (es) 2014-12-23 2017-04-26 Axikin Pharmaceuticals Inc Derivados de 3,5-aminopirazol como inhibidores de quinasa rc

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1950990A1 (de) * 1968-10-17 1970-05-14 Ciba Geigy Verfahren zur Herstellung von neuen triazacyclischen Verbindungen
GB1355513A (en) * 1971-04-07 1974-06-05 May & Baker Ltd Isothiazole derivatives
DE2408234A1 (de) * 1974-02-21 1975-09-04 Celamerck Gmbh & Co Kg Isothiazolylharnstoffe
US4075001A (en) * 1976-06-18 1978-02-21 Fmc Corporation 3-Aminoisothiazole derivatives as herbicides
US4057416A (en) * 1976-06-18 1977-11-08 Fmc Corporation 3-Alkylthio-, 3-alkylsulfinyl-, and 3-alkylsulfonylisothiazole derivatives as herbicides
US4059433A (en) * 1976-06-18 1977-11-22 Fmc Corporation 3-Alkoxyisothiazole derivatives as herbicides
DE3529247A1 (de) * 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
DE3540377A1 (de) * 1985-11-14 1987-05-21 Bayer Ag Thienooxazinone, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer
DE3541631A1 (de) * 1985-11-26 1987-05-27 Bayer Ag Selektiv-fungizide verwendung von thienylharnstoff-derivaten
US4859699A (en) * 1987-07-20 1989-08-22 Sandoz Ltd. Substituted N-benzoyl-N'-thienylureas
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
DE4328425A1 (de) * 1993-08-24 1995-03-02 Basf Ag Acylamino-substituierte Isoxazol- bzw. Isothiazolderivate, Verfahren zu deren Herstellung und ihre Verwendung
TW276256B (es) * 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
JPH10509708A (ja) * 1994-11-10 1998-09-22 コア セラピューティクス，インコーポレイティド プロテイン・キナーゼのインヒビターとして有用な医薬ピラゾール組成物
US5792767A (en) * 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
DE69839639D1 (en) * 1997-05-23 2008-08-07 Bayer Pharmaceuticals Corp Raf kinase hemmer
US6037340A (en) * 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця

Also Published As

Publication number Publication date
EP1187826B1 (en) 2006-12-27
HN2000000051A (es) 2001-02-02
CA2374247A1 (en) 2000-11-30
ATE349440T1 (de) 2007-01-15
BR0010746A (pt) 2002-02-13
JP3692041B2 (ja) 2005-09-07
TNSN00104A1 (fr) 2005-11-10
CO5170417A1 (es) 2002-06-27
AR029634A1 (es) 2003-07-10
AU4137400A (en) 2000-12-12
JP2003500401A (ja) 2003-01-07
US6380214B1 (en) 2002-04-30
DZ3042A1 (fr) 2004-03-27
EP1187826A1 (en) 2002-03-20
ES2276681T3 (es) 2007-07-01
PA8494101A1 (es) 2003-09-05
DE60032601D1 (de) 2007-02-08
CA2374247C (en) 2008-01-22
GT200000069A (es) 2001-11-08
WO2000071532A1 (en) 2000-11-30
JP2005008641A (ja) 2005-01-13
MA26733A1 (fr) 2004-12-20
DE60032601T2 (de) 2007-11-15
MXPA01011920A (es) 2002-05-06
PE20010152A1 (es) 2001-02-08

Similar Documents

Publication Publication Date Title
UY26143A1 (es) Derivados heterocíclicos útiles como agentes anticancerosos
PA8472301A1 (es) Derivados de isotiazol utiles como agentes anticancerosos
DOP2003000694A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
CR6643A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
PA8487601A1 (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
UY26872A1 (es) Derivados de la 4- fenil piridina
PA8490601A1 (es) Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
PA8480101A1 (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos
CO4810375A1 (es) Derivados de 9-amino-3-ceto eritromicina
PA8518701A1 (es) Derivados de tiofeno utiles como agentes anticancerosos
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
BR9805734A (pt) Derivados de imidazolin-4-ona úteis como agentes anticancerìgenos.
AR020032A1 (es) Derivados de 1,3 -metil eritromicina.
BRPI0413876A (pt) tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos
PA8474401A1 (es) 3-ceto derivados triciclicos de 6-0-metileritromicina
PA8450901A1 (es) Derivados de eritromicina
ECSP003474A (es) Derivados heterociclicos utiles como agentes anticancerosos
ECSP992984A (es) Derivados de isotiazol utiles como agentes anticancerosos
ECSP982501A (es) Derivados de eritromicina

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20100518